Paul Drew
Concepts (402)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ethanol | 15 | 2024 | 342 | 5.990 |
Why?
| | Microglia | 28 | 2024 | 113 | 5.380 |
Why?
| | Astrocytes | 10 | 2021 | 137 | 2.420 |
Why?
| | Cerebellum | 8 | 2024 | 125 | 2.160 |
Why?
| | Alcoholism | 4 | 2023 | 239 | 2.110 |
Why?
| | Hippocampus | 9 | 2022 | 201 | 1.920 |
Why?
| | Central Nervous System | 5 | 2020 | 76 | 1.700 |
Why?
| | Multiple Sclerosis | 10 | 2021 | 72 | 1.690 |
Why?
| | Animals | 63 | 2024 | 13505 | 1.520 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 10 | 2014 | 19 | 1.500 |
Why?
| | Mice | 37 | 2024 | 5949 | 1.350 |
Why?
| | Mice, Inbred C57BL | 24 | 2023 | 1884 | 1.320 |
Why?
| | PPAR gamma | 6 | 2017 | 72 | 1.250 |
Why?
| | Animals, Newborn | 10 | 2021 | 362 | 1.150 |
Why?
| | Prostaglandin D2 | 8 | 2011 | 22 | 1.140 |
Why?
| | Cytokines | 19 | 2021 | 623 | 1.120 |
Why?
| | Inflammasomes | 3 | 2024 | 66 | 1.110 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 9 | 2009 | 67 | 1.030 |
Why?
| | Thiazolidinediones | 5 | 2017 | 83 | 0.970 |
Why?
| | Nitric Oxide | 14 | 2012 | 249 | 0.960 |
Why?
| | Disease Models, Animal | 10 | 2024 | 1478 | 0.930 |
Why?
| | Transcription Factors | 13 | 2004 | 566 | 0.920 |
Why?
| | Neurogenesis | 2 | 2021 | 27 | 0.910 |
Why?
| | DNA-Binding Proteins | 7 | 2009 | 422 | 0.900 |
Why?
| | PPAR alpha | 5 | 2009 | 59 | 0.860 |
Why?
| | Brain | 8 | 2013 | 1323 | 0.840 |
Why?
| | Neuroimmunomodulation | 2 | 2014 | 12 | 0.830 |
Why?
| | Immunity | 2 | 2013 | 39 | 0.830 |
Why?
| | Central Nervous System Depressants | 2 | 2013 | 80 | 0.810 |
Why?
| | Retinoid X Receptors | 5 | 2006 | 13 | 0.790 |
Why?
| | Gene Expression Regulation | 13 | 2017 | 990 | 0.780 |
Why?
| | Cells, Cultured | 21 | 2017 | 1567 | 0.780 |
Why?
| | Transcriptome | 2 | 2023 | 370 | 0.760 |
Why?
| | RNA, Messenger | 15 | 2021 | 1132 | 0.740 |
Why?
| | Pregnancy | 10 | 2024 | 2680 | 0.740 |
Why?
| | Interleukin-12 | 3 | 2007 | 27 | 0.730 |
Why?
| | Neurons | 8 | 2017 | 418 | 0.710 |
Why?
| | Zinc Fingers | 5 | 1997 | 23 | 0.680 |
Why?
| | Cerebral Cortex | 9 | 2021 | 198 | 0.660 |
Why?
| | Immunity, Cellular | 3 | 2015 | 64 | 0.630 |
Why?
| | Tretinoin | 5 | 2005 | 54 | 0.610 |
Why?
| | Cell Survival | 11 | 2012 | 612 | 0.590 |
Why?
| | Aging | 2 | 2013 | 701 | 0.580 |
Why?
| | Neuroglia | 4 | 2007 | 39 | 0.580 |
Why?
| | Anti-Inflammatory Agents | 3 | 2020 | 166 | 0.570 |
Why?
| | T-Lymphocytes, Helper-Inducer | 3 | 2017 | 43 | 0.570 |
Why?
| | Encephalomyelitis | 2 | 2017 | 6 | 0.560 |
Why?
| | Alcoholic Neuropathy | 1 | 2016 | 2 | 0.520 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 11 | 2012 | 235 | 0.520 |
Why?
| | Inflammation | 7 | 2012 | 641 | 0.520 |
Why?
| | DNA, Complementary | 8 | 2013 | 135 | 0.510 |
Why?
| | Autoimmunity | 3 | 2011 | 34 | 0.480 |
Why?
| | Lipopolysaccharides | 11 | 2012 | 206 | 0.470 |
Why?
| | Tumor Necrosis Factor-alpha | 9 | 2013 | 399 | 0.460 |
Why?
| | RNA | 4 | 2023 | 168 | 0.460 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2012 | 122 | 0.450 |
Why?
| | Analysis of Variance | 7 | 2012 | 554 | 0.420 |
Why?
| | Encephalitis | 2 | 2006 | 39 | 0.420 |
Why?
| | Drug Interactions | 7 | 2012 | 206 | 0.420 |
Why?
| | Dose-Response Relationship, Drug | 11 | 2014 | 1378 | 0.410 |
Why?
| | Naphthoquinones | 1 | 2012 | 10 | 0.400 |
Why?
| | Mitoxantrone | 1 | 2012 | 9 | 0.400 |
Why?
| | Female | 18 | 2024 | 28171 | 0.390 |
Why?
| | 5-Aminolevulinate Synthetase | 5 | 1990 | 5 | 0.380 |
Why?
| | Nerve Tissue Proteins | 3 | 1997 | 187 | 0.370 |
Why?
| | Oligodendroglia | 2 | 2021 | 35 | 0.360 |
Why?
| | NF-kappa B | 7 | 2006 | 322 | 0.350 |
Why?
| | Colorectal Neoplasms | 3 | 2024 | 294 | 0.350 |
Why?
| | Nitric Oxide Synthase | 5 | 2001 | 62 | 0.340 |
Why?
| | Interleukin-17 | 2 | 2011 | 35 | 0.340 |
Why?
| | Toll-Like Receptor 4 | 2 | 2023 | 51 | 0.330 |
Why?
| | Peroxisome Proliferator-Activated Receptors | 2 | 2006 | 15 | 0.320 |
Why?
| | Fenofibrate | 3 | 2009 | 17 | 0.320 |
Why?
| | Immune Tolerance | 1 | 2009 | 91 | 0.310 |
Why?
| | Chemokine CX3CL1 | 2 | 2021 | 9 | 0.310 |
Why?
| | Toll-Like Receptors | 1 | 2009 | 27 | 0.310 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2021 | 137 | 0.310 |
Why?
| | Humans | 35 | 2024 | 52483 | 0.290 |
Why?
| | Base Sequence | 13 | 1997 | 640 | 0.290 |
Why?
| | Cognition Disorders | 2 | 2021 | 196 | 0.290 |
Why?
| | Molecular Sequence Data | 13 | 1997 | 778 | 0.280 |
Why?
| | Myeloid Differentiation Factor 88 | 2 | 2023 | 34 | 0.280 |
Why?
| | Gene Expression | 5 | 2021 | 618 | 0.270 |
Why?
| | Genes, MHC Class I | 4 | 1995 | 11 | 0.260 |
Why?
| | Gliosis | 1 | 2006 | 4 | 0.260 |
Why?
| | beta 2-Microglobulin | 3 | 1995 | 39 | 0.260 |
Why?
| | Peroxisome Proliferators | 1 | 2005 | 7 | 0.240 |
Why?
| | Prostaglandins A | 1 | 2005 | 2 | 0.240 |
Why?
| | Chemokines | 4 | 2006 | 79 | 0.240 |
Why?
| | Chemokine CCL2 | 3 | 2013 | 69 | 0.230 |
Why?
| | Male | 10 | 2024 | 26761 | 0.230 |
Why?
| | Apoptosis | 2 | 2021 | 1119 | 0.230 |
Why?
| | Sulfonamides | 3 | 2011 | 133 | 0.220 |
Why?
| | Hemin | 3 | 1989 | 7 | 0.220 |
Why?
| | Heme | 3 | 1989 | 21 | 0.220 |
Why?
| | Gonadal Steroid Hormones | 1 | 2003 | 39 | 0.210 |
Why?
| | Nitric Oxide Synthase Type II | 5 | 2008 | 62 | 0.210 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 3 | 2014 | 9 | 0.210 |
Why?
| | Cytokine-Induced Killer Cells | 1 | 2023 | 2 | 0.210 |
Why?
| | Adaptor Proteins, Vesicular Transport | 1 | 2023 | 43 | 0.210 |
Why?
| | Central Nervous System Diseases | 1 | 2003 | 27 | 0.200 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2013 | 185 | 0.200 |
Why?
| | Chromosome Mapping | 3 | 1997 | 154 | 0.200 |
Why?
| | Allylisopropylacetamide | 4 | 1990 | 4 | 0.200 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2023 | 202 | 0.200 |
Why?
| | Interferon-gamma | 5 | 2005 | 180 | 0.190 |
Why?
| | T-Lymphocytes | 3 | 2007 | 340 | 0.190 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2014 | 164 | 0.190 |
Why?
| | Myelin Sheath | 1 | 2021 | 26 | 0.180 |
Why?
| | Herpesvirus 3, Human | 1 | 2001 | 32 | 0.180 |
Why?
| | Interneurons | 1 | 2021 | 32 | 0.180 |
Why?
| | Amino Acid Sequence | 6 | 1997 | 578 | 0.180 |
Why?
| | Estriol | 1 | 2000 | 4 | 0.180 |
Why?
| | Dehydroepiandrosterone | 1 | 2000 | 12 | 0.180 |
Why?
| | Antibodies, Viral | 1 | 2001 | 109 | 0.180 |
Why?
| | Progesterone | 1 | 2000 | 58 | 0.170 |
Why?
| | Chronic Disease | 1 | 2023 | 586 | 0.170 |
Why?
| | Interleukins | 3 | 2011 | 33 | 0.170 |
Why?
| | Liver Neoplasms | 1 | 2024 | 333 | 0.170 |
Why?
| | Cell Cycle | 1 | 2021 | 230 | 0.170 |
Why?
| | Polysaccharides | 2 | 2012 | 57 | 0.170 |
Why?
| | Hydrocortisone | 1 | 2000 | 111 | 0.170 |
Why?
| | Acetamides | 2 | 1990 | 19 | 0.160 |
Why?
| | Estradiol | 1 | 2000 | 214 | 0.160 |
Why?
| | Mice, Transgenic | 6 | 2017 | 552 | 0.150 |
Why?
| | Histocompatibility Antigens Class I | 2 | 1995 | 48 | 0.150 |
Why?
| | Hydroxycholesterols | 1 | 1998 | 9 | 0.150 |
Why?
| | beta-Cyclodextrins | 1 | 1998 | 17 | 0.150 |
Why?
| | Thiazoles | 2 | 2011 | 55 | 0.150 |
Why?
| | Orphan Nuclear Receptors | 2 | 2009 | 14 | 0.150 |
Why?
| | Hydrocarbons, Fluorinated | 2 | 2009 | 8 | 0.150 |
Why?
| | HTLV-I Infections | 1 | 1997 | 3 | 0.140 |
Why?
| | Human T-lymphotropic virus 1 | 1 | 1997 | 4 | 0.140 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 1997 | 4 | 0.140 |
Why?
| | Genes | 1 | 1997 | 31 | 0.140 |
Why?
| | Peptide Fragments | 4 | 2014 | 203 | 0.140 |
Why?
| | Gene Expression Regulation, Viral | 1 | 1997 | 49 | 0.140 |
Why?
| | Receptors, CCR6 | 1 | 2017 | 3 | 0.140 |
Why?
| | Tumor Cells, Cultured | 7 | 2001 | 460 | 0.140 |
Why?
| | Liver | 3 | 1989 | 1156 | 0.140 |
Why?
| | Conserved Sequence | 2 | 1997 | 53 | 0.140 |
Why?
| | Chromosomes, Human, Pair 19 | 1 | 1997 | 8 | 0.140 |
Why?
| | Chromosomes, Human, Pair 7 | 1 | 1997 | 30 | 0.140 |
Why?
| | Antineoplastic Agents | 1 | 2005 | 1222 | 0.140 |
Why?
| | Protein Structure, Tertiary | 1 | 1997 | 242 | 0.140 |
Why?
| | Colonic Polyps | 1 | 2017 | 39 | 0.130 |
Why?
| | Receptors, HIV | 1 | 2016 | 2 | 0.130 |
Why?
| | Receptors, Cytokine | 1 | 2016 | 11 | 0.130 |
Why?
| | Alzheimer Disease | 1 | 2000 | 332 | 0.130 |
Why?
| | Precancerous Conditions | 1 | 2017 | 85 | 0.130 |
Why?
| | Colonoscopy | 1 | 2017 | 108 | 0.130 |
Why?
| | Freund's Adjuvant | 2 | 2014 | 8 | 0.130 |
Why?
| | Transcription, Genetic | 3 | 2009 | 378 | 0.130 |
Why?
| | Sequence Homology, Amino Acid | 4 | 1997 | 140 | 0.130 |
Why?
| | Consensus Sequence | 1 | 1995 | 22 | 0.130 |
Why?
| | Neuroprotective Agents | 1 | 2017 | 101 | 0.120 |
Why?
| | Blotting, Western | 4 | 2009 | 590 | 0.120 |
Why?
| | Adenoma | 1 | 2017 | 113 | 0.120 |
Why?
| | Behavior, Animal | 1 | 2017 | 185 | 0.120 |
Why?
| | Acromegaly | 1 | 2015 | 8 | 0.120 |
Why?
| | Promoter Regions, Genetic | 6 | 2009 | 467 | 0.120 |
Why?
| | Neoplasm Proteins | 1 | 1997 | 334 | 0.120 |
Why?
| | Rats | 5 | 2001 | 3220 | 0.120 |
Why?
| | Memory Disorders | 1 | 2015 | 49 | 0.120 |
Why?
| | Cellular Microenvironment | 1 | 2015 | 30 | 0.120 |
Why?
| | Th17 Cells | 2 | 2014 | 27 | 0.120 |
Why?
| | Phosphoproteins | 1 | 1995 | 119 | 0.120 |
Why?
| | Adipose Tissue, White | 1 | 2015 | 35 | 0.120 |
Why?
| | Growth Hormone | 1 | 2015 | 97 | 0.120 |
Why?
| | Repressor Proteins | 1 | 1995 | 155 | 0.110 |
Why?
| | Ethylenes | 1 | 2014 | 6 | 0.110 |
Why?
| | Cell Line | 5 | 2017 | 1030 | 0.110 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2016 | 197 | 0.110 |
Why?
| | Interleukin-6 | 2 | 2013 | 278 | 0.110 |
Why?
| | Physician-Patient Relations | 1 | 2015 | 143 | 0.110 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2013 | 29 | 0.110 |
Why?
| | Immunohistochemistry | 3 | 2013 | 979 | 0.110 |
Why?
| | Dementia | 1 | 2015 | 134 | 0.110 |
Why?
| | Spleen | 2 | 2012 | 172 | 0.110 |
Why?
| | Interleukin-23 | 2 | 2012 | 10 | 0.110 |
Why?
| | Genes, Regulator | 1 | 1993 | 5 | 0.100 |
Why?
| | Dihydropyridines | 2 | 1990 | 7 | 0.100 |
Why?
| | Communication | 1 | 2015 | 257 | 0.100 |
Why?
| | Testosterone | 3 | 1990 | 141 | 0.100 |
Why?
| | Age Factors | 1 | 2016 | 1132 | 0.100 |
Why?
| | Immunologic Factors | 2 | 2014 | 117 | 0.100 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2012 | 74 | 0.100 |
Why?
| | Fetus | 2 | 2012 | 194 | 0.100 |
Why?
| | Statistics, Nonparametric | 1 | 2012 | 192 | 0.100 |
Why?
| | Cloning, Molecular | 3 | 1997 | 190 | 0.100 |
Why?
| | Stilbenes | 1 | 2012 | 58 | 0.100 |
Why?
| | Chick Embryo | 5 | 1990 | 81 | 0.090 |
Why?
| | Bone Marrow Cells | 1 | 2012 | 190 | 0.090 |
Why?
| | Gemfibrozil | 2 | 2009 | 9 | 0.090 |
Why?
| | Dendritic Cells | 1 | 2012 | 136 | 0.090 |
Why?
| | Mental Disorders | 1 | 2016 | 428 | 0.090 |
Why?
| | Neurodegenerative Diseases | 1 | 2012 | 80 | 0.090 |
Why?
| | Severity of Illness Index | 2 | 2012 | 1026 | 0.090 |
Why?
| | DNA | 4 | 2006 | 549 | 0.090 |
Why?
| | Cell Count | 1 | 2011 | 149 | 0.090 |
Why?
| | Receptors, Retinoic Acid | 2 | 2004 | 22 | 0.080 |
Why?
| | Myelin Proteins | 1 | 2009 | 4 | 0.080 |
Why?
| | Receptors, Interleukin | 1 | 2009 | 10 | 0.080 |
Why?
| | Time Factors | 3 | 2012 | 2968 | 0.080 |
Why?
| | Myelin-Associated Glycoprotein | 1 | 2009 | 8 | 0.080 |
Why?
| | Isoenzymes | 1 | 1989 | 166 | 0.080 |
Why?
| | Inflammation Mediators | 2 | 2007 | 115 | 0.080 |
Why?
| | Infant, Newborn | 1 | 2016 | 2867 | 0.080 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 1990 | 191 | 0.080 |
Why?
| | Adult | 4 | 2024 | 14161 | 0.080 |
Why?
| | Genetic Vectors | 2 | 2001 | 128 | 0.070 |
Why?
| | Brain Abscess | 1 | 2008 | 10 | 0.070 |
Why?
| | Cell Differentiation | 1 | 2011 | 665 | 0.070 |
Why?
| | Adolescent | 2 | 2017 | 6739 | 0.070 |
Why?
| | Cell Proliferation | 2 | 2014 | 1023 | 0.070 |
Why?
| | Blotting, Northern | 3 | 1995 | 106 | 0.070 |
Why?
| | Tissue Distribution | 3 | 1995 | 171 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2009 | 243 | 0.070 |
Why?
| | Antigen-Presenting Cells | 1 | 2007 | 23 | 0.070 |
Why?
| | Nitroprusside | 1 | 2006 | 11 | 0.070 |
Why?
| | Irritable Bowel Syndrome | 1 | 2007 | 17 | 0.070 |
Why?
| | Drug Synergism | 2 | 1998 | 150 | 0.070 |
Why?
| | Leukocytes, Mononuclear | 1 | 2007 | 123 | 0.060 |
Why?
| | Brain Neoplasms | 2 | 2001 | 291 | 0.060 |
Why?
| | Tetrazolium Salts | 1 | 2005 | 15 | 0.060 |
Why?
| | Interferon-alpha | 1 | 2005 | 53 | 0.060 |
Why?
| | Transfection | 4 | 2009 | 357 | 0.060 |
Why?
| | Inhibitory Concentration 50 | 1 | 2005 | 74 | 0.060 |
Why?
| | Autoimmune Diseases | 1 | 2006 | 86 | 0.060 |
Why?
| | Staphylococcus aureus | 2 | 2008 | 338 | 0.060 |
Why?
| | Staphylococcal Infections | 1 | 2008 | 285 | 0.060 |
Why?
| | Microbodies | 1 | 2004 | 3 | 0.060 |
Why?
| | Neuroblastoma | 2 | 1995 | 51 | 0.060 |
Why?
| | Macrophages | 2 | 2008 | 379 | 0.060 |
Why?
| | Purkinje Cells | 1 | 2024 | 15 | 0.060 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2024 | 64 | 0.050 |
Why?
| | Child | 1 | 2016 | 7248 | 0.050 |
Why?
| | Ligands | 3 | 2011 | 206 | 0.050 |
Why?
| | Chromatography, Liquid | 1 | 2024 | 240 | 0.050 |
Why?
| | Peptides | 1 | 2024 | 223 | 0.050 |
Why?
| | Tandem Mass Spectrometry | 1 | 2024 | 251 | 0.050 |
Why?
| | Proteome | 1 | 2024 | 171 | 0.050 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2001 | 13 | 0.050 |
Why?
| | Acetic Acid | 1 | 2001 | 11 | 0.050 |
Why?
| | Neutralization Tests | 1 | 2001 | 27 | 0.050 |
Why?
| | Models, Biological | 1 | 2005 | 735 | 0.050 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2001 | 16 | 0.050 |
Why?
| | Protein Engineering | 1 | 2001 | 20 | 0.050 |
Why?
| | Viral Envelope Proteins | 1 | 2001 | 35 | 0.050 |
Why?
| | Herpes Zoster | 1 | 2001 | 16 | 0.050 |
Why?
| | Proteomics | 1 | 2024 | 329 | 0.050 |
Why?
| | Immunotherapy, Adoptive | 1 | 2023 | 166 | 0.040 |
Why?
| | Neuroimaging | 1 | 2021 | 94 | 0.040 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2001 | 61 | 0.040 |
Why?
| | Aged | 3 | 2024 | 10121 | 0.040 |
Why?
| | Dehydroepiandrosterone Sulfate | 1 | 2000 | 4 | 0.040 |
Why?
| | Meningioma | 1 | 2001 | 47 | 0.040 |
Why?
| | Young Adult | 2 | 2024 | 4329 | 0.040 |
Why?
| | Glycoproteins | 1 | 2001 | 122 | 0.040 |
Why?
| | Nitrites | 1 | 2000 | 31 | 0.040 |
Why?
| | Protein Biosynthesis | 2 | 2017 | 258 | 0.040 |
Why?
| | Glioma | 1 | 2001 | 78 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2023 | 467 | 0.040 |
Why?
| | Radiopharmaceuticals | 1 | 2001 | 204 | 0.040 |
Why?
| | Escherichia coli | 1 | 2001 | 192 | 0.040 |
Why?
| | Neuropsychological Tests | 1 | 2021 | 338 | 0.040 |
Why?
| | Cognition | 1 | 2021 | 331 | 0.040 |
Why?
| | Polymerase Chain Reaction | 2 | 1997 | 461 | 0.040 |
Why?
| | Spinal Cord | 2 | 2014 | 131 | 0.040 |
Why?
| | Cyclodextrins | 1 | 1998 | 18 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2017 | 3392 | 0.040 |
Why?
| | DNA Fragmentation | 1 | 1998 | 55 | 0.040 |
Why?
| | Paraparesis, Tropical Spastic | 1 | 1997 | 1 | 0.040 |
Why?
| | Chromosomes, Artificial, Yeast | 1 | 1997 | 7 | 0.040 |
Why?
| | Leukemia-Lymphoma, Adult T-Cell | 1 | 1997 | 7 | 0.040 |
Why?
| | Genetic Code | 1 | 1997 | 3 | 0.040 |
Why?
| | Drosophila melanogaster | 1 | 1997 | 32 | 0.040 |
Why?
| | Mammals | 1 | 1997 | 61 | 0.040 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 1997 | 36 | 0.040 |
Why?
| | Species Specificity | 1 | 1997 | 192 | 0.030 |
Why?
| | South Australia | 1 | 2017 | 3 | 0.030 |
Why?
| | RNA Stability | 1 | 2017 | 25 | 0.030 |
Why?
| | Autoimmune Diseases of the Nervous System | 1 | 2017 | 9 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2001 | 481 | 0.030 |
Why?
| | Medical Audit | 1 | 2017 | 22 | 0.030 |
Why?
| | 3' Untranslated Regions | 1 | 2017 | 55 | 0.030 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 1997 | 96 | 0.030 |
Why?
| | Hospitals, Teaching | 1 | 2017 | 54 | 0.030 |
Why?
| | Rectum | 1 | 2017 | 55 | 0.030 |
Why?
| | Hyperplasia | 1 | 2017 | 98 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 1 | 2000 | 1563 | 0.030 |
Why?
| | RNA Interference | 1 | 2017 | 181 | 0.030 |
Why?
| | Prospective Studies | 1 | 2023 | 2481 | 0.030 |
Why?
| | Saccharomyces cerevisiae | 1 | 1997 | 176 | 0.030 |
Why?
| | Colon | 1 | 2017 | 104 | 0.030 |
Why?
| | Evolution, Molecular | 1 | 1997 | 93 | 0.030 |
Why?
| | Rats, Wistar | 1 | 2017 | 193 | 0.030 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2017 | 89 | 0.030 |
Why?
| | Cell Movement | 1 | 2017 | 268 | 0.030 |
Why?
| | Interferon Regulatory Factor-2 | 1 | 1995 | 3 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 1997 | 245 | 0.030 |
Why?
| | Interferon Regulatory Factor-1 | 1 | 1995 | 14 | 0.030 |
Why?
| | Stimulation, Chemical | 1 | 1995 | 27 | 0.030 |
Why?
| | Pregnancy Complications | 1 | 2000 | 400 | 0.030 |
Why?
| | Measles virus | 1 | 1995 | 8 | 0.030 |
Why?
| | Transcription Factor TFIIIA | 1 | 1995 | 1 | 0.030 |
Why?
| | Rana pipiens | 1 | 1995 | 2 | 0.030 |
Why?
| | Mumps virus | 1 | 1995 | 10 | 0.030 |
Why?
| | Motor Activity | 1 | 2017 | 223 | 0.030 |
Why?
| | Gene Library | 1 | 1995 | 44 | 0.030 |
Why?
| | Interferon-beta | 1 | 1995 | 33 | 0.030 |
Why?
| | Xenopus laevis | 1 | 1995 | 40 | 0.030 |
Why?
| | Video Recording | 1 | 2015 | 81 | 0.030 |
Why?
| | Stromal Cells | 1 | 2015 | 79 | 0.030 |
Why?
| | Memory | 1 | 2015 | 100 | 0.030 |
Why?
| | Ambulatory Care Facilities | 1 | 2015 | 124 | 0.030 |
Why?
| | Oncogene Protein v-akt | 1 | 2014 | 11 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2021 | 1546 | 0.030 |
Why?
| | HIV-1 | 1 | 1994 | 59 | 0.030 |
Why?
| | Cell Polarity | 1 | 2014 | 16 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2017 | 879 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 1995 | 229 | 0.030 |
Why?
| | Databases, Factual | 1 | 2017 | 706 | 0.030 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 1993 | 42 | 0.030 |
Why?
| | Myelin Basic Protein | 2 | 2004 | 5 | 0.030 |
Why?
| | Adipose Tissue | 1 | 2015 | 204 | 0.030 |
Why?
| | MicroRNAs | 1 | 2017 | 387 | 0.030 |
Why?
| | Enhancer Elements, Genetic | 1 | 1993 | 58 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 582 | 0.030 |
Why?
| | Interleukin-12 Subunit p40 | 1 | 2012 | 3 | 0.030 |
Why?
| | Lymphocyte Activation | 2 | 2004 | 172 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1046 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2017 | 1678 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2012 | 155 | 0.020 |
Why?
| | Nuclear Receptor Subfamily 1, Group F, Member 1 | 1 | 2011 | 2 | 0.020 |
Why?
| | Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2011 | 4 | 0.020 |
Why?
| | Drug Inverse Agonism | 1 | 2011 | 18 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2023 | 6607 | 0.020 |
Why?
| | Middle Aged | 2 | 2017 | 13028 | 0.020 |
Why?
| | HEK293 Cells | 1 | 2011 | 229 | 0.020 |
Why?
| | Enzyme Induction | 1 | 1990 | 77 | 0.020 |
Why?
| | Models, Molecular | 1 | 2011 | 348 | 0.020 |
Why?
| | Ferrous Compounds | 1 | 1989 | 10 | 0.020 |
Why?
| | Aminolevulinic Acid | 1 | 1989 | 8 | 0.020 |
Why?
| | RNA Probes | 1 | 1989 | 3 | 0.020 |
Why?
| | Enzyme Stability | 1 | 1989 | 21 | 0.020 |
Why?
| | Half-Life | 1 | 1989 | 88 | 0.020 |
Why?
| | GATA3 Transcription Factor | 1 | 2009 | 7 | 0.020 |
Why?
| | Interleukin-5 | 1 | 2009 | 6 | 0.020 |
Why?
| | T-Box Domain Proteins | 1 | 2009 | 14 | 0.020 |
Why?
| | Interleukin-4 | 1 | 2009 | 44 | 0.020 |
Why?
| | Risk Factors | 1 | 2017 | 3889 | 0.020 |
Why?
| | Microbial Viability | 1 | 2008 | 32 | 0.020 |
Why?
| | Fibronectins | 1 | 2008 | 37 | 0.020 |
Why?
| | Phagocytosis | 1 | 2008 | 53 | 0.020 |
Why?
| | Cell Wall | 1 | 2008 | 59 | 0.020 |
Why?
| | Proteoglycans | 1 | 2008 | 87 | 0.020 |
Why?
| | Polyribosomes | 1 | 1987 | 7 | 0.020 |
Why?
| | Signal Transduction | 1 | 2014 | 1671 | 0.020 |
Why?
| | Nucleic Acid Hybridization | 1 | 1987 | 56 | 0.020 |
Why?
| | Dicarbethoxydihydrocollidine | 1 | 1986 | 2 | 0.020 |
Why?
| | Models, Immunological | 1 | 2006 | 8 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2007 | 86 | 0.020 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2007 | 323 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2008 | 891 | 0.020 |
Why?
| | Antigens, Surface | 1 | 2004 | 47 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2004 | 5 | 0.010 |
Why?
| | Th2 Cells | 1 | 2004 | 23 | 0.010 |
Why?
| | Growth Inhibitors | 1 | 2004 | 26 | 0.010 |
Why?
| | Cell Line, Transformed | 1 | 2004 | 74 | 0.010 |
Why?
| | Anxiety | 1 | 2007 | 300 | 0.010 |
Why?
| | T-Lymphocyte Subsets | 1 | 2004 | 41 | 0.010 |
Why?
| | Immunization | 1 | 2004 | 69 | 0.010 |
Why?
| | Drug Combinations | 1 | 2004 | 132 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2007 | 1201 | 0.010 |
Why?
| | Cell Nucleus | 2 | 1994 | 187 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2004 | 405 | 0.010 |
Why?
| | Genes, T-Cell Receptor | 1 | 2002 | 5 | 0.010 |
Why?
| | Adoptive Transfer | 1 | 2002 | 29 | 0.010 |
Why?
| | Lymph Nodes | 1 | 2004 | 258 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2004 | 478 | 0.010 |
Why?
| | Depression | 1 | 2007 | 600 | 0.010 |
Why?
| | Neoplasm Transplantation | 1 | 2001 | 87 | 0.010 |
Why?
| | Biotransformation | 1 | 2001 | 85 | 0.010 |
Why?
| | Carbon Radioisotopes | 1 | 2001 | 54 | 0.010 |
Why?
| | Transplantation, Heterologous | 1 | 2001 | 79 | 0.010 |
Why?
| | Radionuclide Imaging | 1 | 2001 | 107 | 0.010 |
Why?
| | Kinetics | 1 | 2002 | 626 | 0.010 |
Why?
| | Poly I-C | 1 | 1995 | 6 | 0.010 |
Why?
| | HIV Long Terminal Repeat | 1 | 1994 | 4 | 0.010 |
Why?
| | Oligonucleotide Probes | 1 | 1994 | 19 | 0.010 |
Why?
| | NF-kappa B p50 Subunit | 1 | 1994 | 17 | 0.010 |
Why?
| | Transcription Factor RelA | 1 | 1994 | 32 | 0.010 |
Why?
| | Virus Latency | 1 | 1994 | 53 | 0.010 |
Why?
| | Genome, Viral | 1 | 1994 | 83 | 0.010 |
Why?
| | Carcinoma, Embryonal | 1 | 1993 | 1 | 0.010 |
Why?
| | Embryonal Carcinoma Stem Cells | 1 | 1993 | 2 | 0.010 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 1993 | 47 | 0.010 |
Why?
| | Up-Regulation | 1 | 1995 | 454 | 0.010 |
Why?
| | Binding Sites | 1 | 1994 | 377 | 0.010 |
Why?
| | DNA Primers | 1 | 1993 | 208 | 0.010 |
Why?
| | Neoplastic Stem Cells | 1 | 1993 | 99 | 0.010 |
Why?
|
|
Drew's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|